Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLPT 
Clearpoint Neuro Inc (CLPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.94% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 361.71M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 280020 | Beta 1.07 | 52 Weeks Range 5.11 - 19.22 | Updated Date 04/1/2025 |
52 Weeks Range 5.11 - 19.22 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.26% | Operating Margin (TTM) -72.11% |
Management Effectiveness
Return on Assets (TTM) -30.16% | Return on Equity (TTM) -81.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 312288750 | Price to Sales(TTM) 11.52 |
Enterprise Value 312288750 | Price to Sales(TTM) 11.52 | ||
Enterprise Value to Revenue 9.95 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 27632300 | Shares Floating 25368691 |
Shares Outstanding 27632300 | Shares Floating 25368691 | ||
Percent Insiders 8.01 | Percent Institutions 33.26 |
Analyst Ratings
Rating 5 | Target Price 17 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Clearpoint Neuro Inc
Company Overview
History and Background
ClearPoint Neuro, Inc. (formerly MRI Interventions, Inc.) was founded in 1998. The company focuses on developing and commercializing innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, real-time MRI guidance. It has evolved from a research-focused entity to a commercial enterprise with a growing installed base and a pipeline of products targeting neurological disorders.
Core Business Areas
- Neuro Navigation: ClearPoint Neuro's core business centers around the ClearPoint System, a neuro-navigation platform used for minimally invasive delivery of therapies to the brain. The system integrates with MRI scanners to provide real-time visualization and guidance during procedures.
- Drug Delivery: The company develops and offers products for targeted drug delivery to the brain. This includes cannulas and infusion systems designed to deliver therapeutics directly to specific areas within the brain.
- Biologics and Gene Therapies: ClearPoint Neuro collaborates with pharmaceutical and biotech companies to enable clinical trials and commercialization of novel biologics and gene therapies targeting neurological diseases.
Leadership and Structure
Joe Burnett is the CEO. The company is structured with departments for R&D, marketing, sales, operations, and regulatory affairs. There is a board of directors overseeing the company's strategy and performance.
Top Products and Market Share
Key Offerings
- ClearPoint System: The ClearPoint System is a neuro-navigation platform utilized for minimally invasive procedures within the brain. It offers real-time MRI guidance. While exact market share data is not readily available, ClearPoint is a notable player in the MRI-guided neurosurgery market, which is estimated to grow. Competitors include Medtronic and other companies offering surgical navigation systems. Revenue from this product is the core revenue driver for the company, though specific numbers are not readily available publically.
- SmartFlow Cannula: A critical component for drug delivery in the brain. Market share is difficult to pinpoint but Clearpoint is a leader in convection enhanced delivery, which utilizes the SmartFlow Cannula. Competitors include standard cannulas that lack active infusion capabilities.
Market Dynamics
Industry Overview
The industry is characterized by increasing demand for minimally invasive neurosurgical procedures, driven by aging populations and advancements in neurotherapeutics. Growth is fuelled by innovation in biologics and gene therapies for neurological disorders, creating a need for precise delivery methods.
Positioning
ClearPoint Neuro is positioned as a provider of MRI-guided neuro-navigation and drug delivery solutions. Its competitive advantage lies in its integration with MRI technology, allowing for real-time visualization and precise targeting during procedures.
Total Addressable Market (TAM)
The TAM for neurosurgical navigation and drug delivery is estimated to be in the billions of dollars, with the market for gene therapy delivery specifically growing rapidly. ClearPoint Neuro is well-positioned to capture a share of this market by providing enabling technology for advanced therapies.
Upturn SWOT Analysis
Strengths
- MRI-guided technology
- Strong partnerships with pharmaceutical and biotech companies
- Focus on minimally invasive procedures
- Growing installed base of ClearPoint Systems
Weaknesses
- Limited revenue compared to larger competitors
- Reliance on regulatory approvals for new products
- Relatively small sales and marketing team
- High operating costs
Opportunities
- Expanding applications of gene and cell therapies
- Increasing adoption of minimally invasive neurosurgery
- Development of new neurotherapeutic agents
- Partnerships with research institutions
Threats
- Competition from established medical device companies
- Technological obsolescence
- Changes in reimbursement policies
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- SNY
- ABT
Competitive Landscape
ClearPoint Neuro has a competitive advantage in MRI-guided neuro-navigation. However, larger competitors like Medtronic have greater financial resources and a broader product portfolio. Clearpoint must focus on partnerships to expand their product applications.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: ClearPoint Neuro has shown revenue growth driven by increased adoption of its ClearPoint System and growth in its drug delivery business. However, it has also faced challenges in achieving profitability.
Future Projections: Analysts project continued revenue growth for ClearPoint Neuro, driven by increasing demand for minimally invasive neurosurgery and advancements in neurotherapeutics. Future profitability is dependent on scaling operations and managing costs effectively.
Recent Initiatives: Recent initiatives include expanding the applications of the ClearPoint System, forging partnerships with pharmaceutical companies for clinical trials, and developing new drug delivery technologies.
Summary
ClearPoint Neuro is a growing company focused on MRI-guided neuro-navigation and drug delivery. The company has a strong technological advantage and strategic partnerships. Profitability is a key area to monitor. The company must compete against larger competitors.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MDT
Medtronic PLC
MDT
Medtronic PLC
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearpoint Neuro Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2020-02-12 | President, CEO & Director Mr. Joseph Michael Burnett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 115 | Website https://www.clearpointneuro.com |
Full time employees 115 | Website https://www.clearpointneuro.com | ||
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.